Biotechnology - San Diego, California, United States
Cylene Pharmaceuticals ceased operation in 2013. It was a clinical stage private company designing and developing small molecule drugs against newly validated cancer targets. Cylene's leadership in exploiting CK2 pathways enabled rational drug combinations for improved treatment outcomes against many cancer indications. The Company's Pol I program provided a non-genotoxic mechanism for activating p53 to kill cancer cells.
Apache
Google Font API
Google AdSense
Amazon AWS
YouTube
Mobile Friendly